Project Ambition

The MycoSynVac project aims at using cutting-edge synthetic biology methods to engineer Mycoplasma pneumoniae as a universal chassis for vaccination. We will (1) modify existing methods of genome transplantation used for Mycoplasma species, (2) develop serum-free medium for scale-up in bioreactors and (3) analyze how to bring the product to market after efficacy of the vaccine has been shown in animal studies, ultimately to fight Mycoplasma infections in farm animals.

 

  • Luis Serrano awarded the FEBS National Lecturer prize at the Congress of the Italian Federation of Life Sciences (FISV)
  • Prize for MycoSynVac poster at IOM 2018
  • Following our last two events this year in Linz and Bristol we held a final event for 2017 in Berlin, Germany on October 27. For this event we again...
  • Disease & Impact
  • Dr Carmen DE VICENTE COLL Research Programme Officer, European Commission
  • Infection caused by Mycoplasma species on livestock result in multi-million losses in Europe and USA
  • Current production processes of vaccines based on mycoplasma are very irreproducible and prone to contamination by animal viruses.